Tokyo, Japan, April 20, 2014 --(PR.com
)-- Hawk Trade says that Christopher Atkinson, a senior vice-president at the Tokyo-based private equity house who joined the advisory board at “Gerontology-Solutions,” has signaled that he intends to accelerate the commencement of human trials for the company’s anti-aging treatment codenamed ‘Regenoderm’.
Mr. Atkinson joined the advisory board at Gerontology Solutions to help drive commercialization of key therapies developed by the innovative anti-senescence company.
A Hawk Trade analyst said, “While the scientists and specialists at Gerontology Solutions are firmly committed to their craft, they felt they needed the expertise of a professional with experience of monetizing assets from within a broad range of disciplines and Christopher was happy to provide his assistance.”
Up until now, the Regenoderm treatment has been restricted to testing on rats but highly encouraging results from those tests have prompted the company to consider controlled human trials.
Mr. Atkinson is expected to begin gathering the appropriate authorizations as well as the sourcing and interviewing of test subjects for a tentative start date in the 3rd quarter of 2014.
The Regenoderm treatment reportedly enables skin to begin making its own collagen thereby delaying the signs of aging by a considerable degree. The Gerontology Solutions treatment’s advantage over current collagen supplementary offerings is its ability to stimulate production of the individual’s own personal collagen rather than introducing foreign materials from animal-based sources.
“This treatment has the potential to generate a great deal of income for Gerontology Solutions while helping a great number of individuals who wish to delay the signs of aging,” concluded the Hawk Trade analyst.
About Hawk Trade:
Since our inception in 2007, Hawk Trade has focused on delivering exceptional investment performance to our clients both corporate and individual, by coupling entrepreneurial drive with deep industry expertise and robust risk management.
High net worth clients depend on our tailored innovative solutions and on seizing the right opportunities at the most optimum moment. We align ourselves with corporate clients to help them attain all of their capital market requirements.
Our business has grown on the principles of formulating strong partnerships with our clients and maintaining these through integrity and innovation. In the pursuit of excellence for both our firm and our clients, we remain committed to the highest ethical standards.
About Gerontology Solutions:
Gerontology Solutions is dedicated to developing and marketing small-molecule therapeutics derived from genetic and phosphatase platforms and nutritional health supplements that help maintain vigour and functionality as we age.
Through research on protein networks that control biological systems, Gerontology Solutions is developing therapeutic agents for Alzheimer's, Parkinson's and other neurodegenerative diseases. Our technology provides many opportunities for the development of innovative pharmaceutical therapeutics.